Predictive Oncology (POAI) 10-Q 12 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 07, 2021
Document Information [Line Items]
Entity Registrant Name	Predictive Oncology Inc.
Entity Central Index Key	0001446159
Trading Symbol	poai
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		49,818,784
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 27,299,407	$ 678,332
Accounts Receivable	264,928	256,878
Inventories	292,824	289,535
Prepaid Expense and Other Assets	344,921	289,490
Total Current Assets	28,202,080	1,514,235
Fixed Assets, net	3,975,453	3,822,700
Intangibles, net	3,316,489	3,398,101
Lease Right-of-Use Assets	1,229,773	1,395,351
Other Long-Term Assets	116,257	116,257
Goodwill	2,813,792	2,813,792
Total Assets	39,653,844	13,060,436
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable	1,027,000	1,372,070
Notes Payable – Net of Discounts of $0 and $244,830		4,431,925
Accrued Expenses and other liabilities	1,277,943	2,588,047
Derivative Liability	198,711	294,382
Deferred Revenue	154,195	53,028
Lease Liability	603,054	597,469
Total Current Liabilities	3,260,903	9,336,921
Lease Liability – Net of current portion	684,756	845,129
Other long-term liabilities	163,098	235,705
Total Liabilities	4,108,757	10,417,755
Stockholders’ Equity:
Common Stock, $.01 par value, 100,000,000 shares authorized, 48,794,320 and 19,804,787 outstanding	487,944	198,048
Additional paid-in capital	147,328,172	110,826,949
Accumulated Deficit	(112,271,821)	(108,383,108)
Total Stockholders’ Equity	35,545,087	2,642,681
Total Liabilities and Stockholders’ Equity	39,653,844	13,060,436
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 and 79,246 shares outstanding	$ 792	$ 792

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Discount of note payable	$ 0	$ 244,830
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	48,794,320	19,804,787
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, shares outstanding (in shares)	79,246	79,246

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue	$ 280,317	$ 294,943
Cost of goods sold	97,758	92,657
Gross margin	182,559	202,286
General and administrative expense	3,270,777	2,828,476
Operations expense	574,812	548,753
Sales and marketing expense	114,641	264,409
Total operating loss	(3,777,671)	(3,439,352)
Other income	28,259	3
Other expense	(234,972)	(1,117,075)
Gain on derivative instruments	95,671	27,107
Net loss	$ (3,888,713)	$ (4,529,317)
Loss per common share - basic and diluted (in dollars per share)	$ (0.11)	$ (0.93)
Weighted average shares used in computation - basic and diluted (in shares)	36,513,300	4,866,328

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Registered Direct Offerings [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Registered Direct Offerings [Member]Common Stock [Member]	Registered Direct Offerings [Member]Additional Paid-in Capital [Member]	Registered Direct Offerings [Member]Retained Earnings [Member]	Registered Direct Offerings [Member]	Private Placement [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]	Bridge Notes [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Bridge Notes [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Bridge Notes [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Bridge Notes [Member]Common Stock [Member]	Bridge Notes [Member]Additional Paid-in Capital [Member]	Bridge Notes [Member]Retained Earnings [Member]	Bridge Notes [Member]	Series E Preferred Stock Conversions [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Series E Preferred Stock Conversions [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Series E Preferred Stock Conversions [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Series E Preferred Stock Conversions [Member]Common Stock [Member]	Series E Preferred Stock Conversions [Member]Additional Paid-in Capital [Member]	Series E Preferred Stock Conversions [Member]Retained Earnings [Member]	Series E Preferred Stock Conversions [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019																									79,246	3,500,000	258	4,056,652
Balance at Dec. 31, 2019																									$ 792	$ 35,000	$ 3	$ 40,567	$ 93,653,667	$ (82,498,711)	$ 11,231,318
Shares issued pursuant to CEO exchange agreement (in shares)																												50,000
Shares issued pursuant to CEO exchange agreement																												$ 500	129,500		130,000
Inducement shares issued pursuant to promissory note extension (in shares)																												30,000
Inducement shares issued pursuant to promissory note extension																												$ 300	40,950		41,250
Issuance of shares and prefunded warrants pursuant to March 2020 private placement, net (in shares)																												260,000
Issuance of shares and prefunded warrants pursuant to March 2020 private placement, net																												$ 2,600	455,223		457,823
Inducement shares issued pursuant to 2020 convertible debt and warrants (in shares)																												46,875
Inducement shares issued pursuant to 2020 convertible debt and warrants																												$ 468	119,532		120,000
Warrants issued pursuant to 2020 convertible debt																													116,951		116,951
stock issued, conversions (in shares)														170,000						(50)	141,191
stock issued, conversions														$ 1,700	$ 265,628		$ 267,328			$ (1)	$ 1,412	$ (1,411)
Shares issued pursuant to Equity Line (in shares)																												943,000
Shares issued pursuant to Equity Line																												$ 9,430	1,860,469		1,869,899
Shares issued to consultant and other (in shares)																												155,000
Shares issued to consultant and other																												$ 1,550	360,750		362,300
Vesting expense																													287,838		287,838
Net loss																														(4,529,317)	(4,529,317)
Balance (in shares) at Mar. 31, 2020																									79,246	3,500,000	208	5,852,718
Balance at Mar. 31, 2020																									$ 792	$ 35,000	$ 2	$ 58,527	97,289,097	(87,028,028)	10,355,390
Balance (in shares) at Dec. 31, 2020																									79,246			19,804,787
Balance at Dec. 31, 2020																									$ 792			$ 198,048	110,826,949	(108,383,108)	2,642,681
Shares issued pursuant to CEO exchange agreement (in shares)																												100,401
Shares issued pursuant to CEO exchange agreement																												$ 1,004	142,569		143,573
stock issued, conversions (in shares)																												1,107,544
stock issued, conversions																												$ 11,075	502,936		514,011
Vesting expense																													565,082		565,082
Net loss																														(3,888,713)	$ (3,888,713)
Issuance of shares and warrants (in shares)		13,488,098					9,043,766																								22,531,864
Issuance of shares and warrants		$ 134,881	$ 14,877,611		$ 15,012,492		$ 90,438	$ 15,974,301		$ 16,064,739
Exercise of warrants (in shares)																												5,247,059
Exercise of warrants																												$ 52,471	4,442,799		$ 4,495,270
Shares issued to consultant & other (in shares)																												2,665
Shares issued to consultant & other																												$ 27	(4,075)		(4,048)
Balance (in shares) at Mar. 31, 2021																									79,246			48,794,320
Balance at Mar. 31, 2021																									$ 792			$ 487,944	$ 147,328,172	$ (112,271,821)	$ 35,545,087

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flow from operating activities:
Net loss	$ (3,888,713)	$ (4,529,317)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	321,980	206,580
Vesting expense	565,082	287,838
Common stock issued for consulting and other	(4,048)	362,300
Amortization of debt discount	244,830	448,026
Gain on valuation of equity-linked instruments and derivative liability	(95,671)	(27,107)
Debt extinguishment costs		300,000
Equity instruments issued in connection with 2020 convertible debt		16,716
Changes in assets and liabilities:
Accounts receivable	(8,050)	27,278
Inventories	(3,289)	34,473
Prepaid expense and other assets	(55,431)	(62,248)
Accounts payable	(345,070)	(27,121)
Accrued expenses	(82,271)	(14,144)
Deferred revenue	101,167	3,745
Other long-term liabilities	(72,607)
Net cash used in operating activities	(3,322,091)	(2,972,981)
Cash flow from investing activities:
Purchase of fixed assets	(391,685)
Acquisition of intangibles	(1,436)	(32,510)
Net cash used in investing activities:	(393,121)	(32,510)
Cash flow from financing activities:
Proceeds from debt issuance		1,820,000
Proceeds from issuance of common stock and warrants, net	31,077,231	3,127,818
Proceeds from exercise of warrants into common stock	4,495,270
Repayment of debt	(4,162,744)	(821,916)
Payment premium	(1,073,470)	(84,898)
Proceeds from issuance of common stock pursuant to equity line		1,869,899
Net cash provided by financing activities	30,336,287	5,910,903
Net increase in cash and cash equivalents	26,621,075	2,905,412
Cash and cash equivalents at beginning of period	678,332	150,831
Cash and cash equivalents at end of period	27,299,407	3,056,243
Non-cash transactions:
Bridge loan conversion into common stock		267,328
Shares issued to CEO per agreement related to exchange agreement		130,000
Shares issued to CEO per agreement related to accrued interest	143,573
Series E preferred stock conversions		1,412
Inducement shares issued pursuant to convertible debt		103,284
Debt Conversion, Original Debt, Amount	514,011
Inducement shares issued for debt extension		41,250
Put and conversion derivative from debt issuance		120,921
Warrants issued pursuant to debt issuance		$ 116,951

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Predictive Oncology Inc. (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. The Company is a healthcare company that provides personalized medicine solutions and medical devices in two 1 2 In addition, the Company's wholly owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis is presented as part of the condensed consolidated financial statements and is included in corporate in the Company's segment reporting. During the first 2018, 25% April 4, 2019, 75% The Company had cash and cash equivalents of $27,299,407 March 31, 2021. March 31, 2021, no October 2019, $15,000,000 three March 31, 2021, $9,789,419 In January February 2021, $31,077,231 March 1, 2021, $5,906,802 September 2018, September 2019, February 2020 2021 The Company believes that its existing capital resources will be sufficient to support its operating plan at least through June 30, 2022. may twelve Coronavirus Outbreak In March 2020, 19 not 19 19 2020 may 2020. fourth 2020, 19 may Interim Financial Statements The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company's position, the results of its operations, and its cash flows for the interim periods. These interim condensed consolidated financial statements reflect all intercompany eliminations. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto contained in the Annual Report on Form 10 March 15, 2021. may not Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Reclassifications Certain reclassifications have been made to the prior years' condensed consolidated financial statements to conform to the current year presentation. The reclassifications had no Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three no Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management's assessment of the status of individual accounts. Amounts recorded in accounts receivable on the condensed consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not 30 30 not $0 March 31, 2021 December 31, 2020. Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company's investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 7 Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 6 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred. Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying condensed consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not The Company concluded there was no December 31, 2020. September 30, 2020. The Company concluded there was no December 31, 2020. 360. March 31, 2021, no Goodwill In accordance with ASC 350, Intangibles – Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, Simplifying the Test for Goodwill Impairment 3 1 The Company recognized loss on impairment goodwill during the year ended December 31, 2020 $12,876,498. March 31, 2021, no not The Company will continue to monitor its reporting units to determine whether events and circumstances warrant further interim impairment testing. Impairment of goodwill is not no not Leases – ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms. Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company's sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer's contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment. Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company's Tumor Drug Response Testing (formerly ChemoFx) and Genomic Profiling (formerly BioSpeciFx) tests. The Tumor Drug Response test determines how a patient's tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression of a particular gene related to a patient's tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics payment terms vary by the agreements reached with insurance carriers and Medicare. The Company's performance obligations are satisfied at one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect less consideration than it originally estimated for a contract with a patient, it will account for the change as a decrease to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company's efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract's transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company's current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Accounts receivable totaled $264,928 $256,878 March 31, 2021 December 31, 2020, The Company's deferred revenues related primarily to maintenance plans of $154,195 $53,028 March 31, 2021 December 31, 2020, Practical Expedients The Company has elected the practical expedient not Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the three months ended March 31, 2021 2020 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% 82.6% Risk-free interest rate 0.93% - 1.45% 0.70% - 1.57% Expected life (in years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% 82.6% Risk-free interest rate 0.42% - 0.69% 0.54% - 0.79% Expected life (in years) 5 - 5 .5 2 - 5.5 Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $93,629 $129,341 three March 31, 2021 2020, Other Expense Other expense consisted primarily of interest expense, payment premium, amortization of original issue discounts, and loss on debt extinguishment associated to the Company's notes payable. Offering Costs Costs incurred which are direct and incremental to an offering of the Company's securities are deferred and charged against the proceeds of the offering unless such costs are deemed to be insignificant in which case they are expensed as incurred. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2017 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash and cash equivalents with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one not Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023. Recent Developments On March 19, 2021, 71, October 2016 January 2020. Dr. Carl Schwartz retired through his resignation as the Chief Executive Officer of the Company effective on March 19, 2021. 100,000 April 1, 2021. Effective April 21, 2021, 2021 5,000 2012 The Company has evaluated all of its activities and concluded that no Note 11

Note 2 - Inventories

Note 2 - Inventories	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 2 Inventory balances are as follows: As of As of Finished goods $ 96,171 $ 95,898 Raw materials 141,413 151,366 Work-In-Process 55,240 42,271 Total $ 292,824 $ 289,535

Note 3 - Fixed Assets

Note 3 - Fixed Assets	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 3 The Company's fixed assets consist of the following: As of As of Computers, software, and office equipment $ 3,662,822 $ 3,638,520 Leasehold improvements 315,296 315,297 Laboratory equipment 1,402,543 1,035,160 Manufacturing tooling 108,956 108,956 Demo equipment 56,614 56,614 Total 5,546,231 5,154,547 Less: Accumulated depreciation (1,570,778 ) (1,331,847 ) Total Fixed Assets, Net $ 3,975,453 $ 3,822,700 Depreciation expense was $238,932 $130,075 three March 31, 2021 2020,

Note 4 - Intangible Assets

Note 4 - Intangible Assets	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 4 The components of intangible assets were as follows: As of March 31, 2021 As of December 31, 2020 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying Patents & Trademarks $ 402,857 $ (215,597 ) $ 187,260 $ 401,421 $ (211,110 ) $ 190,311 Developed Technology 2,882,000 (288,199 ) 2,593,801 2,882,000 (252,175 ) 2,629,825 Customer Relationships 445,000 (296,667 ) 148,333 445,000 (259,583 ) 185,417 Tradename 398,000 (10,905 ) 387,095 398,000 (5,452 ) 392,548 Total $ 4,127,857 $ (811,368 ) $ 3,316,489 $ 4,126,421 $ (728,320 ) $ 3,398,101 Amortization expense was $83,048 $76,505 three March 31, 2021 2020, The following table outlines the estimated future amortization expense related to intangible assets held as of March 31, 2021: Year ending December 31, Expense 2021 $ 249,182 2022 220,993 2023 183,910 2024 183,910 2025 183,910 Thereafter 2,294,584 Total $ 3,316,489

Note 5 - Notes Payable

Note 5 - Notes Payable	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 5 The balances of notes payable were as follows: Due Date As of As of Promissory note 2019 March 31, 2021 $ - $ 1,490,833 Promissory note 2020 March 31, 2021 - 1,464,146 2018 Investor Loan March 31, 2021 - 1,721,776 Total Notes Payable, gross - 4,676,755 Less: Unamortized discount - (244,830 ) Total Notes Payable, net $ - $ 4,431,925 Promissory Note Conversions Each investor received the right to convert all or any part of its 2018 may March 31, 2020, no first three 2020, $267,328 170,000 Also, the investor in the 2019 2020 $514,011 1,107,544 first 2021 February 15, 2021. Promissory Note Repayment On March 1, 2021, $5,906,802 February 23, 2021, 2018 2019 2020

Note 6 - Stockholders' Equity,

Note 6 - Stockholders' Equity, Stock Options and Warrants	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 6 Equity Line On October 24, 2019, $15,000,000 three 104,651 $450,000 three may March 31, 2021, $9,789,419 Note 11 2021 In January February 2021, five first four one two four one two five one 7.5% 1% 7.5% 125% five five one Offering Shares Sale Investor Exercise Placement Exercise Gross Net January 12, 2021 (registered direct) 3,650,840 $0.842 1,825,420 $0.80 273,813 $1.0525 $3,074,007 $2,731,766 January 21, 2021 (registered direct) 2,200,000 $1.00 1,100,000 $1.00 165,000 $1.25 $2,200,000 $1,932,050 January 26, 2021 (registered direct) 3,414,970 $1.20 1,707,485 $1.37 256,123 $1.50 $4,097,964 $3,668,687 February 16, 2021 (registered direct) 4,222,288 $1.75 2,111,144 $2.00 316,672 $2.1875 $7,389,004 $6,679,989 February 23, 2021 (private placement) 9,043,766 $1.95 4,521,883 $2.00 678,282 $2.4375 $17,635,344 $16,064,739 Total 22,531,864 11,265,932 1,689,890 $34,396,319 $31,077,231 * one one 2021 During the period January 1, 2021 March 31, 2021, 5,247,059 $0.86 $4,495,270. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors, and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 319,851 1.03 8,097,468 1.547 Forfeited (72,728 ) 10.58 (128,710 ) 95.11 Exercised - - (2,786,992 ) 0.79 Outstanding at December 31, 2020 1,013,547 $ 5.41 7,353,376 $ 3.76 Issued 10,680 0.69 12,955,822 1.65 Forfeited (18,078 ) 9.89 - - Exercised - - (5,247,059 ) 0.86 Outstanding at March 31, 2021 1,006,149 $ 5.25 15,062,139 $ 2.96 Stock-based compensation expense recognized for three March 31, 2021 March 31, 2020 $565,082 $287,838, three March, $403,721 $7,357 18

Note 7 - Derivatives

Note 7 - Derivatives	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 7 Certain warrants issued to placement agents were determined to be a derivative liability due to certain features of the warrants which could, in certain circumstances, result in the holder receiving the Black Scholes value of the outstanding warrants in the same type of consideration as the common stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock, therefore, the warrants were classified as a liability. The fair value of the agent warrants issued in connection with the March 2020 $33,654 December 31, 2020. $32,507 three March 31, 2021. March 31, 2021, $66,161. The fair value of the agent warrants issued in connection with the May 2020 $33,819 $65,139 December 31, 2020 March 31, 2021, $31,320 three March 31, 2021. The placement agent warrants issued in connection with the June 2020 $32,701 $67,411 December 31, 2020 March 31, 2021, $34,710 three March 31, 2021. The Company concluded the Promissory Note 2020 815, Derivatives and Hedging two December 31, 2020, $104,529. March 1, 2021, zero $104,529 three March 31, 2021. On September 30, 2020, 2019 2019 815, December 31, 2020, $89,680. March 1, 2021, zero $89,680 three March 31, 2021. The table below discloses changes in value of the Company's embedded derivative liabilities discussed above. Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Gain recognized to revalue derivative instrument at fair value (27,107 ) Derivative liability balance at March 30, 2020 $ 2,814,798 Derivative liability balance at December 31, 2020 $ 294,382 Gain recognized to revalue derivative instrument at fair value (95,671 ) Derivative liability balance at March 31, 2021 $ 198,711

Note 8 - Loss Per Share

Note 8 - Loss Per Share	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 8 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended 2021 2020 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (3,888,713 ) $ (4,529,317 ) Denominator: Weighted average common shares outstanding-basic 36,513,300 4,886,328 Effect of diluted stock options, warrants, and preferred stock (1) - - Weighted average common shares outstanding - diluted 36,513,300 4,886,328 Loss per common share-basic and diluted $ (0.11 ) $ (0.93 ) ( 1 The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Three Months ended 2021 2020 Options 1,006,419 794,038 Warrants 15,062,139 5,663,594 Convertible debt - 378,000 Preferred stock: series B 7,925 7,925 Preferred stock: series D - 350,000 Preferred stock: series E - 691,159

Note 9 - Segments

Note 9 - Segments	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 9 The Company has determined its operating segments in accordance with ASC 280 Segment Reporting The Company has three Note 1 three March 31, 2021 Revenue Three Months Ended 2021 2020 Skyline $ 264,253 $ 279,813 Helomics 1,989 15,130 Soluble 14,075 - Corporate - - Total $ 280,317 $ 294,943 Segment Gain (Loss) Three Months Ended 2021 2020 Skyline $ (142,558 ) $ (409,844 ) Helomics (1,227,676 ) (1,412,465 ) Soluble (249,529 ) - Corporate (2,268,950 ) (2,707,008 ) Total $ (3,888,713 ) $ (4,529,317 ) Assets As of As of 2021 2020 Skyline $ 872,761 $ 1,191,439 Helomics 6,872,046 9,773,902 Soluble 1,849,905 1,883,585 Corporate 30,059,132 211,510 Total $ 39,653,844 $ 13,060,436

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 10 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company's former directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). The Company and GLG have a partnership agreement for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women's cancer. There has been no Richard L. Gabriel is also contracted as the Chief Operating Officer for TumorGenesis. Through April 1, 2019, $12,000 six May 1, 2019, one three $13,500

Note 11 - Subsequent Events

Note 11 - Subsequent Events	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 11 Equity Line Agreement Between April 1, 2021 April 14, 2021, 572,504 $588,590 Resignation of Director Effective May 1, 2021, not

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc. (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. The Company is a healthcare company that provides personalized medicine solutions and medical devices in two 1 2 In addition, the Company's wholly owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis is presented as part of the condensed consolidated financial statements and is included in corporate in the Company's segment reporting. During the first 2018, 25% April 4, 2019, 75% The Company had cash and cash equivalents of $27,299,407 March 31, 2021. March 31, 2021, no October 2019, $15,000,000 three March 31, 2021, $9,789,419 In January February 2021, $31,077,232 March 1, 2021, $5,906,802 September 2018, September 2019, February 2020 2021 The Company believes that its existing capital resources will be sufficient to support its operating plan at least through June 30, 2022. may twelve
Effect of Covid-19 Pandemic [Policy Text Block]	Coronavirus Outbreak In March 2020, 19 not 19 19 2020 may 2020. fourth 2020, 19 may
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the prior years' condensed consolidated financial statements to conform to the current year presentation. The reclassifications had no
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three no
Receivable [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management's assessment of the status of individual accounts. Amounts recorded in accounts receivable on the condensed consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not 30 30 not $0 March 31, 2021 December 31, 2020.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company's investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 7
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 6 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying condensed consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not The Company concluded there was no December 31, 2020. September 30, 2020. The Company concluded there was no December 31, 2020. 360. March 31, 2021, no
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC 350, Intangibles – Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, Simplifying the Test for Goodwill Impairment 3 1 The Company recognized loss on impairment goodwill during the year ended December 31, 2020 $12,876,498. March 31, 2021, no not The Company will continue to monitor its reporting units to determine whether events and circumstances warrant further interim impairment testing. Impairment of goodwill is not no not
Lessee, Leases [Policy Text Block]	Leases – ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company's sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer's contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment. Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company's Tumor Drug Response Testing (formerly ChemoFx) and Genomic Profiling (formerly BioSpeciFx) tests. The Tumor Drug Response test determines how a patient's tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression of a particular gene related to a patient's tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics payment terms vary by the agreements reached with insurance carriers and Medicare. The Company's performance obligations are satisfied at one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect less consideration than it originally estimated for a contract with a patient, it will account for the change as a decrease to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company's efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract's transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company's current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Accounts receivable totaled $264,928 $256,878 March 31, 2021 December 31, 2020, The Company's deferred revenues related primarily to maintenance plans of $154,195 $53,028 March 31, 2021 December 31, 2020, Practical Expedients The Company has elected the practical expedient not
Valuation and Accounting for Stock Options and Warrants, Policy [Policy Text Block]	Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the three months ended March 31, 2021 2020 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% 82.6% Risk-free interest rate 0.93% - 1.45% 0.70% - 1.57% Expected life (in years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% 82.6% Risk-free interest rate 0.42% - 0.69% 0.54% - 0.79% Expected life (in years) 5 - 5 .5 2 - 5.5
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $93,629 $129,341 three March 31, 2021 2020,
Other Expense Policy [Policy Text Block]	Other Expense Other expense consisted primarily of interest expense, payment premium, amortization of original issue discounts, and loss on debt extinguishment associated to the Company's notes payable.
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company's securities are deferred and charged against the proceeds of the offering unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2017
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash and cash equivalents with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one not
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023.

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers, software and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 6 Demo equipment 3
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	For the three months ended March 31, 2021 2020 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% 82.6% Risk-free interest rate 0.93% - 1.45% 0.70% - 1.57% Expected life (in years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% 82.6% Risk-free interest rate 0.42% - 0.69% 0.54% - 0.79% Expected life (in years) 5 - 5 .5 2 - 5.5

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of As of Finished goods $ 96,171 $ 95,898 Raw materials 141,413 151,366 Work-In-Process 55,240 42,271 Total $ 292,824 $ 289,535

Note 3 - Fixed Assets (Tables)

Note 3 - Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of As of Computers, software, and office equipment $ 3,662,822 $ 3,638,520 Leasehold improvements 315,296 315,297 Laboratory equipment 1,402,543 1,035,160 Manufacturing tooling 108,956 108,956 Demo equipment 56,614 56,614 Total 5,546,231 5,154,547 Less: Accumulated depreciation (1,570,778 ) (1,331,847 ) Total Fixed Assets, Net $ 3,975,453 $ 3,822,700

Note 4 - Intangible Assets (Tab

Note 4 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of March 31, 2021 As of December 31, 2020 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying Patents & Trademarks $ 402,857 $ (215,597 ) $ 187,260 $ 401,421 $ (211,110 ) $ 190,311 Developed Technology 2,882,000 (288,199 ) 2,593,801 2,882,000 (252,175 ) 2,629,825 Customer Relationships 445,000 (296,667 ) 148,333 445,000 (259,583 ) 185,417 Tradename 398,000 (10,905 ) 387,095 398,000 (5,452 ) 392,548 Total $ 4,127,857 $ (811,368 ) $ 3,316,489 $ 4,126,421 $ (728,320 ) $ 3,398,101
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending December 31, Expense 2021 $ 249,182 2022 220,993 2023 183,910 2024 183,910 2025 183,910 Thereafter 2,294,584 Total $ 3,316,489

Note 5 - Notes Payable (Tables)

Note 5 - Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Short-term Debt [Table Text Block]	Due Date As of As of Promissory note 2019 March 31, 2021 $ - $ 1,490,833 Promissory note 2020 March 31, 2021 - 1,464,146 2018 Investor Loan March 31, 2021 - 1,721,776 Total Notes Payable, gross - 4,676,755 Less: Unamortized discount - (244,830 ) Total Notes Payable, net $ - $ 4,431,925

Note 6 - Stockholders' Equity_2

Note 6 - Stockholders' Equity, Stock Options and Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Sales of Stock [Table Text Block]	Offering Shares Sale Investor Exercise Placement Exercise Gross Net January 12, 2021 (registered direct) 3,650,840 $0.842 1,825,420 $0.80 273,813 $1.0525 $3,074,007 $2,731,766 January 21, 2021 (registered direct) 2,200,000 $1.00 1,100,000 $1.00 165,000 $1.25 $2,200,000 $1,932,050 January 26, 2021 (registered direct) 3,414,970 $1.20 1,707,485 $1.37 256,123 $1.50 $4,097,964 $3,668,687 February 16, 2021 (registered direct) 4,222,288 $1.75 2,111,144 $2.00 316,672 $2.1875 $7,389,004 $6,679,989 February 23, 2021 (private placement) 9,043,766 $1.95 4,521,883 $2.00 678,282 $2.4375 $17,635,344 $16,064,739 Total 22,531,864 11,265,932 1,689,890 $34,396,319 $31,077,231
Share-based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 319,851 1.03 8,097,468 1.547 Forfeited (72,728 ) 10.58 (128,710 ) 95.11 Exercised - - (2,786,992 ) 0.79 Outstanding at December 31, 2020 1,013,547 $ 5.41 7,353,376 $ 3.76 Issued 10,680 0.69 12,955,822 1.65 Forfeited (18,078 ) 9.89 - - Exercised - - (5,247,059 ) 0.86 Outstanding at March 31, 2021 1,006,149 $ 5.25 15,062,139 $ 2.96

Note 7 - Derivatives (Tables)

Note 7 - Derivatives (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Gain recognized to revalue derivative instrument at fair value (27,107 ) Derivative liability balance at March 30, 2020 $ 2,814,798 Derivative liability balance at December 31, 2020 $ 294,382 Gain recognized to revalue derivative instrument at fair value (95,671 ) Derivative liability balance at March 31, 2021 $ 198,711

Note 8 - Loss Per Share (Tables

Note 8 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended 2021 2020 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (3,888,713 ) $ (4,529,317 ) Denominator: Weighted average common shares outstanding-basic 36,513,300 4,886,328 Effect of diluted stock options, warrants, and preferred stock (1) - - Weighted average common shares outstanding - diluted 36,513,300 4,886,328 Loss per common share-basic and diluted $ (0.11 ) $ (0.93 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months ended 2021 2020 Options 1,006,419 794,038 Warrants 15,062,139 5,663,594 Convertible debt - 378,000 Preferred stock: series B 7,925 7,925 Preferred stock: series D - 350,000 Preferred stock: series E - 691,159

Note 9 - Segments (Tables)

Note 9 - Segments (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended 2021 2020 Skyline $ 264,253 $ 279,813 Helomics 1,989 15,130 Soluble 14,075 - Corporate - - Total $ 280,317 $ 294,943 Three Months Ended 2021 2020 Skyline $ (142,558 ) $ (409,844 ) Helomics (1,227,676 ) (1,412,465 ) Soluble (249,529 ) - Corporate (2,268,950 ) (2,707,008 ) Total $ (3,888,713 ) $ (4,529,317 ) As of As of 2021 2020 Skyline $ 872,761 $ 1,191,439 Helomics 6,872,046 9,773,902 Soluble 1,849,905 1,883,585 Corporate 30,059,132 211,510 Total $ 39,653,844 $ 13,060,436

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Apr. 21, 2021	Apr. 01, 2021	Mar. 01, 2021	Oct. 24, 2019	Oct. 31, 2019	Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Apr. 04, 2019	Mar. 31, 2018
Cash and Cash Equivalents, at Carrying Value, Ending Balance							$ 27,299,407		$ 678,332
Long-term Debt, Total							0
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs						$ 31,077,231	31,077,231	$ 3,127,818
Repayments of Debt							4,162,744	821,916
Accounts Receivable, Allowance for Credit Loss, Current							0		0
Goodwill, Impairment Loss									12,876,498
Accounts Receivable, after Allowance for Credit Loss, Total							264,928		256,878
Contract with Customer, Liability, Total							154,195		53,028
Research and Development Expense, Total							93,629	$ 129,341
Income Tax Expense (Benefit), Total							0
Unrecognized Tax Benefits, Ending Balance							0
Subsequent Event [Member] | Amended and Restated 2012 Stock Incentive Plan [Member] | Board of Directors Chairman [Member]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)	5,000
Dr. Carl Schwartz [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)		100,000
Licensing Agreements [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total									$ 0
Debt Issued in September 2018, September, 2019, and February 2020 [Member]
Repayments of Debt			$ 5,906,802
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised				$ 15,000,000
Sale of Stock, Remaining Available Balance							9,789,419
Equity Line Purchase Agreement [Member] | Investor [Member]
Issuance or Sale of Equity, Can Be Raised					$ 15,000,000
Sale of Equity, Term (Year)					3 years
Sale of Stock, Remaining Available Balance							$ 9,789,419
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage											25.00%
Business Acquisition, Percentage of Voting Interests Acquired										75.00%

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	3 Months Ended
	Mar. 31, 2021
Minimum [Member] | Office Equipment [Member]
Computers, software and office equipment (Year)	3 years
Minimum [Member] | Leasehold Improvements [Member]
Computers, software and office equipment (Year)	2 years	[1]
Minimum [Member] | Manufacturing Tooling [Member]
Computers, software and office equipment (Year)	3 years
Minimum [Member] | Laboratory Equipment [Member]
Computers, software and office equipment (Year)	4 years
Maximum [Member] | Office Equipment [Member]
Computers, software and office equipment (Year)	10 years
Maximum [Member] | Leasehold Improvements [Member]
Computers, software and office equipment (Year)	5 years	[1]
Maximum [Member] | Manufacturing Tooling [Member]
Computers, software and office equipment (Year)	7 years
Maximum [Member] | Laboratory Equipment [Member]
Computers, software and office equipment (Year)	6 years
[1]	Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2021yr	Mar. 31, 2020yr
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	84.80%	82.60%
Expected life (in years) (Year)	10 years	10 years
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.848	0.826
Minimum [Member]
Risk-free interest rate	0.93%	0.70%
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0042	0.0054
Minimum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5	2
Maximum [Member]
Risk-free interest rate	1.45%	1.57%
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0069	0.0079
Maximum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.5	5.5

Note 2 - Inventories - Schedule

Note 2 - Inventories - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Finished goods	$ 96,171	$ 95,898
Raw materials	141,413	151,366
Work-In-Process	55,240	42,271
Total	$ 292,824	$ 289,535

Note 3 - Fixed Assets (Details

Note 3 - Fixed Assets (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Depreciation, Total	$ 238,932	$ 130,075

Note 3 - Fixed Assets - Schedul

Note 3 - Fixed Assets - Schedule of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property, Plant, and Equipment Gross	$ 5,546,231	$ 5,154,547
Less: Accumulated depreciation	(1,570,778)	(1,331,847)
Total Fixed Assets, Net	3,975,453	3,822,700
Office Equipment [Member]
Property, Plant, and Equipment Gross	3,662,822	3,638,520
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	315,296	315,297
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	1,402,543	1,035,160
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,956	108,956
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 56,614	$ 56,614

Note 4 - Intangible Assets (Det

Note 4 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Amortization of Intangible Assets, Total	$ 83,048	$ 76,505

Note 4 - Intangible Assets - Co

Note 4 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Accumulated Amortization	$ (811,368)	$ (728,320)
Net Carrying Amount	3,316,489
Total, Gross Carrying Costs	4,127,857	4,126,421
Total, Net Carrying Amount	3,316,489	3,398,101
Trade Names 1 [Member]
Tradename		398,000
Tradename		(5,452)
Tradename		392,548
Patents and Trademarks [Member]
Gross Carrying Costs	402,857	401,421
Accumulated Amortization	(215,597)	(211,110)
Net Carrying Amount	187,260	190,311
Developed Technology Rights [Member]
Gross Carrying Costs	2,882,000	2,882,000
Accumulated Amortization	(288,199)	(252,175)
Net Carrying Amount	2,593,801	2,629,825
Customer Relationships [Member]
Gross Carrying Costs	445,000	445,000
Accumulated Amortization	(296,667)	(259,583)
Net Carrying Amount	148,333	$ 185,417
Trade Names [Member]
Tradename	398,000
Tradename	(10,905)
Tradename	$ 387,095

Note 4 - Intangible Assets - Es

Note 4 - Intangible Assets - Estimated Future Amortization Expense (Details)	Mar. 31, 2021USD ($)
2021	$ 249,182
2022	220,993
2023	183,910
2024	183,910
2025	183,910
Thereafter	2,294,584
Total	$ 3,316,489

Note 5 - Notes Payable (Details

Note 5 - Notes Payable (Details Textual) - USD ($)	Mar. 01, 2021	Mar. 31, 2021	Mar. 31, 2020
Debt Conversion, Original Debt, Amount		$ 514,011
Repayments of Debt		4,162,744	$ 821,916
Debt Issued in September 2018, September, 2019, and February 2020 [Member]
Repayments of Debt	$ 5,906,802
Conversion of 2018 Investor Loan into Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 267,328
Debt Conversion, Converted Instrument, Shares Issued (in shares)		170,000
Conversion of 2019 and 2020 Investor Promissory Notes into Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 514,011
Debt Conversion, Converted Instrument, Shares Issued (in shares)		1,107,544

Note 5 - Notes Payable - Notes

Note 5 - Notes Payable - Notes Payable (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Notes Payable, Gross		$ 4,676,755
Less: Unamortized discount		(244,830)
Notes Payable		4,431,925
Promissory Note, One [Member]
Notes Payable, Gross		1,490,833
Promissory Note, Two [Member]
Notes Payable, Gross		1,464,146
Convertible Promissory Note [Member]
Notes Payable, Gross		$ 1,721,776

Note 6 - Stockholders' Equity_3

Note 6 - Stockholders' Equity, Stock Options and Warrants (Details Textual) - USD ($)	Oct. 24, 2019	Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2020
Stock Issued During Period, Shares, New Issues (in shares)			22,531,864
Sale of Stock, Agent Placement Fee, Percent of Gross Proceeds		7.50%
Sale of Stock, Management Fee, Percent of Gross Proceeds		1.00%
Proceeds from Warrant Exercises			$ 4,495,270
Share-based Payment Arrangement, Expense			565,082	$ 287,838
Share-based Payment Arrangement, Accelerated Cost			403,721
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			$ 7,357
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Month)			1 year 180 days
Maximum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)			10 years
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			3 years
Investor Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)			5,247,059
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.86
Proceeds from Warrant Exercises			$ 4,495,270
Placement Agent Warrants [Member]
Sale of Stock, Placement Agent, Warrants Assigned, Number of Securities Called by Warrants, Percent of Shares Sold		7.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Stock Price		125.00%
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised	$ 15,000,000
Stock Issued During Period, Shares, New Issues (in shares)	104,651
Stock Issued During Period, Value, New Issues	$ 450,000
Sale of Stock, Remaining Available Balance			9,789,419
Registered Direct Offerings [Member]
Stock Issued During Period, Value, New Issues			15,012,492
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)		1
Registered Direct Offerings [Member] | Investor Warrants [Member]
Warrants and Rights Outstanding, Term (Year)		5 years 182 days
Registered Direct Offerings [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Private Placement [Member]
Stock Issued During Period, Value, New Issues			$ 16,064,739
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)		1
Private Placement [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)		5 years 182 days

Note 6 - Stockholders' Equity_4

Note 6 - Stockholders' Equity, Stock Options and Warrants - Stock Offerings (Details) - USD ($)		2 Months Ended	3 Months Ended
		Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2020
Shares issued (in shares)			22,531,864
Gross proceeds			$ 34,396,319
Net proceeds		$ 31,077,231	$ 31,077,231	$ 3,127,818
Investor Warrants [Member]
Warrants issued (in shares)			11,265,932
Warrants issued, exercise price (in dollars per share)			$ 0.86
Placement Agent Warrants [Member]
Warrants issued (in shares)			1,689,890
January 12, 2021 Registered Direct Offering [Member]
Shares issued (in shares)			3,650,840
Shares issued, price per share (in dollars per share)	[1]		$ 0.842
Gross proceeds			$ 3,074,007
Net proceeds			$ 2,731,766
January 12, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)			1,825,420
Warrants issued, exercise price (in dollars per share)			$ 0.80
January 12, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)			273,813
Warrants issued, exercise price (in dollars per share)			$ 1.0525
January 21, 2021 Registered Direct Offering [Member]
Shares issued (in shares)			2,200,000
Shares issued, price per share (in dollars per share)	[1]		$ 1
Gross proceeds			$ 2,200,000
Net proceeds			$ 1,932,050
January 21, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)			1,100,000
Warrants issued, exercise price (in dollars per share)			$ 1
January 21, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)			165,000
Warrants issued, exercise price (in dollars per share)			$ 1.25
January 26, 2021 Registered Direct Offering [Member]
Shares issued (in shares)			3,414,970
Shares issued, price per share (in dollars per share)	[1]		$ 1.20
Gross proceeds			$ 4,097,964
Net proceeds			$ 3,668,687
January 26, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)			1,707,485
Warrants issued, exercise price (in dollars per share)			$ 1.37
January 26, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)			256,123
Warrants issued, exercise price (in dollars per share)			$ 1.50
February 16, 2021 Registered Direct Offering [Member]
Shares issued (in shares)			4,222,288
Shares issued, price per share (in dollars per share)	[1]		$ 1.75
Gross proceeds			$ 7,389,004
Net proceeds			$ 6,679,989
February 16, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)			2,111,144
Warrants issued, exercise price (in dollars per share)			$ 2
February 16, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)			316,672
Warrants issued, exercise price (in dollars per share)			$ 2.1875
Febuary 23, 2021 Private Placement [Member]
Shares issued (in shares)			9,043,766
Shares issued, price per share (in dollars per share)	[1]		$ 1.95
Gross proceeds			$ 17,635,344
Net proceeds			$ 16,064,739
Febuary 23, 2021 Private Placement [Member] | Investor Warrants [Member]
Warrants issued (in shares)			4,521,883
Warrants issued, exercise price (in dollars per share)			$ 2
Febuary 23, 2021 Private Placement [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)			678,282
Warrants issued, exercise price (in dollars per share)			$ 2.4375
[1]	Sale price includes one share and a warrant to purchase one-half share.

Note 6 - Stockholders' Equity_5

Note 6 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Warrant [Member]
Number of Shares Outstanding (in shares)	7,353,376	2,171,610
Average Exercise Price Outstanding (in dollars per share)	$ 3.76	$ 15.26
Number of Shares Issued (in shares)	12,955,822	8,097,468
Average Exercise Price Issued (in dollars per share)	$ 1.65	$ 1.547
Number of Shares Forfeited (in shares)		(128,710)
Average Exercise Price Forfeited (in dollars per share)		$ 95.11
Number of Shares Exercised (in shares)	(5,247,059)	(2,786,992)
Average Exercise Price Exercised (in dollars per share)	$ 0.86	$ 0.79
Number of Shares Outstanding (in shares)	15,062,139	7,353,376
Average Exercise Price Outstanding (in dollars per share)	$ 2.96	$ 3.76
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	1,013,547	766,424
Average Exercise Price Outstanding (in dollars per share)	$ 5.41	$ 11.34
Number of Shares Issued (in shares)	10,680	319,851
Average Exercise Price Issued (in dollars per share)	$ 0.69	$ 1.03
Number of Shares Forfeited (in shares)	(18,078)	(72,728)
Average Exercise Price Forfeited (in dollars per share)	$ 9.89	$ 10.58
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	1,006,149	1,013,547
Average Exercise Price Outstanding (in dollars per share)	$ 5.25	$ 5.41

Note 7 - Derivatives (Details T

Note 7 - Derivatives (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 01, 2021	Dec. 31, 2020
Agent Warrants In Connection With March 2020 Private Placement [Member]
Derivative Liability, Total	$ 66,161		$ 33,654
Derivative, Gain (Loss) on Derivative, Net, Total	32,507
Agent Warrants Issued In connection With May 2020 Offering [Member]
Derivative Liability, Total	65,139		33,819
Derivative, Gain (Loss) on Derivative, Net, Total	31,320
Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total	67,411		32,701
Derivative, Gain (Loss) on Derivative, Net, Total	34,710
Promissory Note 2020 Conversion Feature [Member]
Derivative Liability, Total		$ 0	104,529
Derivative, Gain (Loss) on Derivative, Net, Total	104,529
Promissory Note 2019 Conversion Feature Agent Warrants [Member]
Derivative Liability, Total		$ 0	$ 89,680
Derivative, Gain (Loss) on Derivative, Net, Total	$ 89,680

Note 7 - Derivatives - Change i

Note 7 - Derivatives - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Derivative liability balance	$ 294,382	$ 50,989
Gain recognized to revalue derivative instrument at fair value	(95,671)	(27,107)
Derivative liability balance	$ 198,711	2,814,798
A, B and Agent Warrants [Member]
Derivative instrument recognized		2,669,995
Promissory Note 2020 [Member]
Derivative instrument recognized		$ 120,921

Note 8 - Loss Per Share - Share

Note 8 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Net loss attributable to common shareholders per common share: basic and diluted calculation		$ (3,888,713)	$ (4,529,317)
Weighted average common shares outstanding-basic (in shares)		36,513,300	4,886,328
Effect of diluted stock options, warrants, and preferred stock (1) (in shares)	[1]
Weighted average common shares outstanding - diluted (in shares)		36,513,300	4,886,328
Loss per common share-basic and diluted (in dollars per share)		$ 0.11	$ 0.93
[1]	The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

Note 8 - Loss Per Share - Antid

Note 8 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	1,006,419	794,038
Warrant [Member]
Antidilutive Securities (in shares)	15,062,139	5,663,594
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)		378,000
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	7,925	7,925
Series D Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)		350,000
Series E Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)		691,159

Note 9 - Segments (Details Text

Note 9 - Segments (Details Textual)	3 Months Ended
	Mar. 31, 2021
Number of Operating Segments	3

Note 9 - Segments - Segments (D

Note 9 - Segments - Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue	$ 280,317	$ 294,943
Net loss	(3,888,713)	(4,529,317)
Assets	39,653,844		$ 13,060,436
Corporate, Non-Segment [Member]
Revenue
Net loss	(2,268,950)	(2,707,008)
Assets	30,059,132		211,510
Skyline [Member] | Operating Segments [Member]
Revenue	264,253	279,813
Net loss	(142,558)	(409,844)
Assets	872,761		1,191,439
Helomics Segment [Member] | Operating Segments [Member]
Revenue	1,989	15,130
Net loss	(1,227,676)	(1,412,465)
Assets	6,872,046		9,773,902
Soluble [Member] | Operating Segments [Member]
Revenue	14,075
Net loss	(249,529)
Assets	$ 1,849,905		$ 1,883,585

Note 10 - Related Party Trans_2

Note 10 - Related Party Transactions (Details Textual) - USD ($)	May 01, 2019	Apr. 01, 2019
Director [Member]
Related Party Transaction, Monthly Cash Payment	$ 13,500	$ 12,000

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - USD ($)	Apr. 14, 2021	Oct. 24, 2019	Mar. 31, 2021
Stock Issued During Period, Shares, New Issues (in shares)			22,531,864
Equity Line Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		104,651
Stock Issued During Period, Value, New Issues		$ 450,000
Equity Line Purchase Agreement [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	572,504
Stock Issued During Period, Value, New Issues	$ 588,590